Skip to main content
Hansa Biopharma logo

Hansa Biopharma — Investor Relations & Filings

Ticker · HNSA ISIN · SE0002148817 LEI · 549300LLEO25ZJJ3NT91 ST Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2016-06-15 Regulatory Filings
Country SE Sweden
Listing ST HNSA

About Hansa Biopharma

https://www.hansabiopharma.com/

Hansa Biopharma is a commercial-stage biopharmaceutical company that develops and commercializes treatments for rare immunologic diseases. The company's core focus is its proprietary antibody-cleaving enzyme technology platform, designed to target and inactivate immunoglobulin G (IgG) antibodies. This approach aims to inhibit harmful IgG-mediated immune responses. Its lead product, imilfidase, is used to enable kidney transplantation in highly sensitized patients who have a low probability of finding a compatible donor. The company is also advancing its enzyme technology to address unmet medical needs in other therapeutic areas, including acute autoimmune diseases, gene therapy, and oncology, where IgG antibodies can be a barrier to treatment or a driver of the disease.

Recent filings

Filing Released Lang Actions
Framgångsrik desensitisering med IdeS i samtliga inkluderade patienter i pågående amerikansk fas II-studie
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESSMEDDELANDE" (Press Release) dated June 15, 2016. It announces the presentation of positive data from an ongoing Phase II clinical study (IdeS in kidney transplantation) at the 2016 American Transplant Congress (ATC). This type of announcement, detailing clinical trial progress and results presentation, is typically classified as an Earnings Release (ER) if it were quarterly results, or more generally, a Regulatory Filing (RNS) if it doesn't fit a more specific category like ER or CT. Since it is a specific announcement about clinical trial progress and data presentation, and not a full financial report (10-K, IR), a management discussion (MDA), or a formal regulatory filing like a DIRS or DIV, the most appropriate general category for a non-standard, time-sensitive corporate update that isn't a formal financial report is RNS (Regulatory Filings/General Regulatory Announcements). Given the content is a scientific/clinical update, it is not a standard ER, but RNS serves as the best fit among the provided options for a general corporate announcement not covered elsewhere.
2016-06-15 Swedish
Inledande resultat från den pågående svenska fas II-studien med IdeS i sensitiserade transplantationspatienter presenteras vid TTS 2016
Regulatory Filings Classification · 99% confidence The document is a press release dated May 31, 2016, announcing that preliminary results from an ongoing Phase II clinical study involving the drug IdeS will be presented at the TTS 2016 congress in August 2016. It explicitly states that an 'Abstract' (sammanfattning) of the upcoming presentation has been made public on the congress website. The document itself is a short announcement detailing the content of this abstract and providing general company information. Since the document is short and its primary function is to announce the publication of an abstract/presentation summary (rather than being the full report, like an ER or IR), it fits the criteria for a Report Publication Announcement (RPA). It is not a general regulatory filing (RNS) because a more specific category (RPA) applies to announcements about the release of other reports/presentations.
2016-05-31 Swedish
Initial results from the ongoing Swedish Phase II study with IdeS in sensitized kidney transplant patients will be presented at TTS 2016
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated May 31, 2016. It discusses preliminary results from a clinical study (Phase II with IdeS) that will be presented at an upcoming conference (TTS 2016). It provides key findings and context about the drug development program. This format—a short, timely announcement of clinical data or corporate news—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (10-K, IR), a management discussion (MDA), or a formal presentation (IP), and it is announcing specific, time-sensitive operational/clinical data, it fits best as an Earnings Release (ER) if it were tied to a reporting period, or more generally, a Regulatory Filing (RNS) as it is a press release disclosing material information. Given the content focuses on clinical trial updates and preliminary data presentation, it is a material corporate announcement. Since there is no specific category for 'Clinical Trial Update Announcement', and it is a short press release disclosing material information, RNS is the most appropriate fallback, although ER is often used for interim operational updates. However, RNS covers general regulatory announcements and press releases that don't fit elsewhere. I will classify it as RNS as it is a general press release disclosing operational/clinical progress, not strictly financial results highlights (ER).
2016-05-31 English
Pågående amerikansk studie visar att IdeS möjliggör transplantation för högsensitiserade patienter
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESSMEDDELANDE" (Press Release) dated May 17, 2016. It announces preliminary positive results from a clinical study (IdeS for kidney transplantation) and states that Professor Stanley Jordan will present the data at the 2016 American Transplant Congress. The final paragraph confirms this is information that the company must disclose according to securities market laws. Since this is an announcement of clinical trial progress and presentation details, and not a full financial report (10-K, IR) or a formal regulatory filing like a dividend notice or insider trade, it best fits the category for general regulatory announcements or news releases. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing scientific/clinical progress, as there is no specific category for 'Clinical Trial Updates' or 'Press Releases'. The document length (3770 chars) is short, but it is the primary source of information, not an announcement *about* another report, so RPA is less suitable than RNS for this type of substantive news.
2016-05-17 Swedish
Ongoing US study shows that IdeS allows for transplantation of highly sensitized patients
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "PRESS RELEASE" dated May 17, 2016. It discusses clinical trial results for a drug (IdeS) and announces that initial results will be presented at the American Transplant Congress (ATC). It also contains boilerplate information about the company (Hansa Medical AB) and concludes with a statement about disclosure pursuant to Swedish securities laws. This format—a brief announcement of new information, often clinical or operational, released to the public via press release—does not fit the specific definitions for 10-K, IR, ER, or IP. Since it is a general, time-sensitive announcement that doesn't fit the other specific categories (like DIRS, DIV, CAP, etc.), it falls best under the general regulatory/miscellaneous announcement category, which is RNS (Regulatory Filings). Although it is an announcement of data presentation, it is not a formal 'Report Publication Announcement' (RPA) which usually announces the release of a formal financial report like an Annual Report or Interim Report.
2016-05-17 English
Hansa Medical utser Henk Doude van Troostwijk till Vice President, Commercial Operations
Board/Management Information Classification · 99% confidence The document is a press release dated May 12, 2016, announcing the appointment of a new executive, Henk Doude van Troostwijk, as Vice President, Commercial Operations. This announcement details changes in the company's senior management team. According to the definitions, the 'Board/Management Information' category (Code: MANG) covers the 'Announcement of changes in the company's board of directors or senior management.' The document explicitly details a new senior management hire.
2016-05-12 Swedish

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.